300199 Hybio Pharmaceutical
- 9.10
- -0.11-1.19%
Hybio Pharmaceutical News
hybio pharmaceutical (300199.SZ): Aseganotide injection approved for market
On September 18, Golonghui reported that Hybio Pharmaceutical (300199.SZ) recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration (Acceptance No.: CYHS2200468, CYHS2200469). The company's "Exenatide Injection" has obtained drug registration approval. Exenatide is a glucagon-like peptide-1 (GLP-1) analog, used to improve blood sugar control in patients with type 2 diabetes, suitable for patients who do not achieve adequate blood sugar control with metformin alone, sulfonylureas alone, or metformin in combination with sulfonylureas.
Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Hybio Pharmaceutical Gets Nod to Market Somatostatin in Europe
Hybio Pharmaceutical (300199.SZ): The active pharmaceutical ingredient of somatostatin has obtained the CEP certificate.
On September 4th, Hybio Pharmaceutical (300199.SZ) announced that the company's somatostatin active pharmaceutical ingredient has received the CEP certificate (Certificate of Suitability to the European Pharmacopoeia) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Somatostatin is a cyclic peptide consisting of fourteen amino acids that is artificially synthesized and has the same chemical structure and mechanism of action as natural somatostatin. Physiological somatostatin is mainly found in the hypothalamus and gastrointestinal tract. Intravenous administration of somatostatin can: 1) inhibit the secretion of growth hormone, thyroid-stimulating hormone, insulin, and glucagon; and 2) inhibit the secretion of gastric acid.
Hybio Pharmaceutical: Summary of Half-Year Report in 2024.
Hybio Pharmaceutical: Half-year report for the year 2024.
Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations
①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.
hybio pharmaceutical (300199.SZ): net loss of 10.3588 million yuan in the first half of the year.
Hybio Pharmaceutical (300199.SZ) announced the interim report for the first half of 2024, with reported revenue of 0.256 billion yuan, a year-on-year decrease of 21.38%; net income attributable to shareholders of the listed company was -10.3588 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -59.7238 million yuan; basic earnings per share was -0.01 yuan.
Hybio Pharmaceutical (SZSE:300199) Pulls Back 6.7% This Week, but Still Delivers Shareholders Favorable 21% CAGR Over 3 Years
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Hybio Pharmaceutical (300199.SZ): Han Yu Dali obtained an industrial cannabis processing license through re-evaluation and replacement.
On July 18th, Gelonhui reported that Hybio Pharmaceutical (300199.SZ) recently applied for an extension to the local department and passed the on-site re-evaluation inspection of the Public Security Bureau in Dali, and finally obtained the renewal of the Industrial Cannabis Processing License in Yunnan Province.
Hybio Pharmaceutical Secures Chilean Medical Approval for Injectable Medication
Hybio Pharmaceutical (300199.SZ): Injection Terlipressin has obtained market authorization in Chile.
On July 4th, Gelunhui reported that Hybio pharmaceutical (300199.SZ) announced that recently, Shenzhen Hybio pharmaceutical co., LTD. received the approval certificate for injection terlipressin issued by the national drug management agency of Chile (ANAMED). Indications of injection terlipressin: treatment of esophageal variceal bleeding.
Hybio Pharmaceutical (300199.SZ): Hybio's Active Pharmaceutical Ingredient for Salmon Calcitonin in Wuhan has obtained the approval notice for market application.
On June 28, 2024, hybio pharmaceutical (wuhan), a wholly-owned subsidiary of Shenzhen hybio pharmaceutical co., ltd. (hereinafter referred to as hybio wuhan), received the approval letter of chemical raw materials for salmon calcitonin issued by the State Administration for drug supervision and management (acceptance number: cyhs2360154). Salmon calcitonin is one of the hormones that regulate calcium metabolism and inhibit the parathyroid gland. It can significantly reduce the loss of bone calcium in high-turnover bone diseases such as osteoporosis, dysplasia and painful neuropathic malnutrition.
Hybio Pharmaceutical (300199.SZ): Tilapornide active pharmaceutical ingredient obtains US DMF registration number.
On June 27th, Gelonhui reported that Hybio Pharmaceutical (300199.SZ) received confirmation from the US Food and Drug Administration (FDA) on June 27th, 2024 that the submitted Thiopeptide Drugmaster file (DMF) had been received.
Hybio Pharmaceutical (300199.SZ): Liraglutide Injection received tentative approval from the FDA in the USA.
On June 24th, Gelunhui reported that Hybio Pharmaceutical (300199.SZ) recently received a notice from the U.S. Food and Drug Administration (FDA). The abbreviated new drug application (ANDA), Liraglutide injection jointly filed by Hybio Pharmaceutical and Hikma Pharmaceuticals USA, Inc., has received tentative approval from the FDA. Tentative Approval indicates that the FDA has completed all the generic drug evaluation requirements, and the drug has undergone
Hybio Pharmaceutical Co., Ltd. (SZSE:300199) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
We Think Hybio Pharmaceutical (SZSE:300199) Has A Fair Chunk Of Debt
3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection
Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical
Analysis
Price Target
No Data
No Data